Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Currently, there is limited evidence showing increased resolution of HS flares with higher
doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile
between the doses. The goal of this study is to determine the efficacy of treating HS flares
with ILTAC-10, ILTAC-20 and ILTAC-40 and to investigate the side effect profile for each
dose.